Search Results
Dec 08, 2025, 09:07 ET PrimeXBT Empowers the Future through Education in South Africa
can afford the high risk of losing your money. The Company does not accept clients from the Restricted Jurisdictions as indicated on its website / T&Cs. Some products and services, including MT5, may not be available in your jurisdiction. The applicable legal entity and its respective products and
More news about: PrimeXBT
Dec 08, 2025, 09:01 ET Pacsun Drops Exclusive Fashion Line with The Metropolitan Museum of Art for the Holidays
Fairytale Mesh Long Sleeve Top create artsy, elevated looks for parties or evening outings. Everyday pieces like the flattering Modelbüch Skimmer T-Shirt and adorable
More news about: Pacsun
Dec 08, 2025, 09:01 ET Massage Envy Announces Scholarship Sweepstakes Winners
to support the next generation of massage therapists.The October 2025 sweepstakes winners are:Kaylee B.Daniza T.Brendan H.Meagan P.Blanca S.Rachel S.Kellen S.Destinee D"Every time we connect with
More news about: Massage Envy
Dec 08, 2025, 09:00 ET Crunch Franchise Brings State-of-the-Art Crunch 3.0 Gym to San Antonio, Texas
members will join for only $1 down and will get their first month free, along with a one hour personal training session, a gym bag, water bottle, and t-shirt.Crunch San Antonio Thousand Oaks will be inviting over 100 individuals to join the team to help their community experience fitness, wellness,
More news about: Crunch Fitness
Dec 08, 2025, 09:00 ET Monster Energy's Joshua Van Defeats Alexandre Pantoja to Claim UFC Flyweight World Championship Title at UFC 323
their Middleweight division fight.UFC 323: Dvalishvili vs Yan 2 was contested in front of a live crowd of 18,603 spectators inside sold-out T-Mobile Arena in Las Vegas. Featuring two UFC World Championship fights and a total of five bouts on the Main Card, the spectacle was broadcast live on
More news about: Monster Energy
Dec 08, 2025, 08:57 ET Intervention de Cui Li, directrice du développement de ZTE, à la conférence « AI Innovation Asia 2025 » (« Innovation en Asie dans le domaine de l'IA 2025 »), organisée par Economist Impact
le délai de dépannage de 47 %.Q2 : Transformation stratégique – Comment le développement de l'autonomie numérique grâce à l'IA agentique va-t-elle refaçonner la construction de la résilience et de l'adaptabilité des organisations ?En fait, nous vivons actuellement une période de grande
More news about: ZTE Corporation
Dec 08, 2025, 08:00 ET Pierre Fabre Pharmaceuticals Announces Updated Phase 3 Tabelecleucel Data at American Society of Hematology Meeting in Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
is an allogeneic, off-the-shelf, EBV-specific T-cell immunotherapy designed to selectively target and eliminate EBV-infected cells. Unlike autologous CAR-T therapies, allogeneic T-cells are derived from third-party donors and are not genetically modified. T-cells are collected from the blood of healthy
More news about: Pierre Fabre Pharmaceuticals
Dec 08, 2025, 08:00 ET Ouro Medicines Receives U.S. FDA Orphan Drug Designation for Gamgertamig (OM336) for Immune Thrombocytopenia
immune reset therapeutics for people living with chronic, immune-mediated diseases, today announced that gamgertamig (OM336), the company's BCMAxCD3 T cell engager antibody candidate, has been granted U.S. Food and Drug Administration (FDA) Orphan Drug Designation (ODD) for development in the treatment
More news about: Ouro Medicines
Dec 08, 2025, 08:00 ET Buy It Now, Thank Us Later: Hagerty's 2026 Bull Market List of 11 Appreciation-Ready Enthusiast Cars
priced out of contemporary 911s and the like.1968–1970 Dodge Charger ($91,450): Roughly 40,000 Chargers were built in high-performance R/T specification, which could be optioned with the meanest engine available: the 425-hp, 426-cubic-inch Hemi V-8. 52% of owners are Gen Xers and younger.1956–1957
More news about: Hagerty
Dec 08, 2025, 07:50 ET TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
TAMs and MDSCs, alleviate T-cell dysfunction, and potentially overcome resistance to checkpoint blockade and other immunotherapies.Dr. James Bianco, President and Chief Executive Officer of TuHURA Biosciences, said "Innate immune cells, MDSCs, TAMs, and adaptive regulatory T cells (Tregs) are among
More news about: TuHURA Biosciences, Inc.
Dec 08, 2025, 07:30 ET Contango ORE and Dolly Varden Silver Announce Merger to Create a New North American High-Grade, Mid-Tier Silver & Gold Producer and Developer
completed a 56,131 meter drill program with initial highlights including 1,422 g/t silver over 21.70 meters at the Wolf Vein deposit (see September 2, 2025 press release), 26.74 g/t gold over 14.76 meters and 14.50 g/t gold and 75 g/t silver over 21.18 meters at the Homestake Silver deposit (see November 10,
More news about: Contango Ore
Dec 08, 2025, 07:30 ET Recordati Rare Diseases Showcases Real-World Evidence Studies That Advance Understanding of Castleman Disease (CD) at the American Society of Hematology (ASH) Annual Meeting
Hematology (ASH) Annual Meeting and Exposition, Orlando, Fla., December 7, 2025. Poster #3009.4 Nishimura Y, Brent B, Dacus KC, Habermann T, Dispensieri A. Comprehensive analysis of subtype-specific outcomes and management in Castleman disease: a 20-year cohort study. Presented at 67th
More news about: Recordati
Dec 08, 2025, 07:00 ET Triple T Transport Expands with New Office in St. Augustine, Florida
www.triplettransport.com.About Triple T TransportFounded in 1988, Triple T Transport is a trusted provider of third-party logistics services, delivering reliable freight brokerage and supply chain solutions
More news about: Triple T Transport Inc
Dec 08, 2025, 07:00 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
UCB: US CommunicationsBecky MaloneT +1.919.605.9600Email [email protected] Communications, Media RelationsLaurent Schots T +32.2.559.92.64
More news about: UCB
Dec 08, 2025, 07:00 ET HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025
FBDB™ platform, and we look forward to engaging with the global hematology community as we expand HCB101 into hematologic malignancies and macrophage/T-cell combination strategies.""Presenting these data at ASH marks an important step for HanchorBio and our team," added Dr. Alvin Luk. "Moving
More news about: HanchorBio Inc.
Dec 08, 2025, 05:25 ET Voranigo® (vorasidenib) de Servier remporte le Prix Galien dans plusieurs pays
van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., Ducray, F., Umemura, Y., Nabors, B., Holdhoff, M., Hottinger, A. F., Arakawa, Y., Sepulveda, J. M., Wick, W., Soffietti, R., … Cloughesy, T. F. (2023). Vorasidenib in idh1- or
More news about: Servier
Dec 08, 2025, 05:14 ET Servier's Voranigo® (vorasidenib) Receives Prix Galien Awards Across Multiple Regions
van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., Ducray, F., Umemura, Y., Nabors, B., Holdhoff, M., Hottinger, A. F., Arakawa, Y., Sepulveda, J. M., Wick, W., Soffietti, R., … Cloughesy, T. F. (2023). Vorasidenib in idh1- or
More news about: Servier
Dec 08, 2025, 05:05 ET Servier's Voranigo® (vorasidenib) Receives Prix Galien Awards Across Multiple Regions
van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., Ducray, F., Umemura, Y., Nabors, B., Holdhoff, M., Hottinger, A. F., Arakawa, Y., Sepulveda, J. M., Wick, W., Soffietti, R., … Cloughesy, T. F. (2023). Vorasidenib in idh1- or
More news about: Servier
Dec 08, 2025, 04:00 ET ELFBAR franchit une étape audacieuse en matière de design sobre avec son kit de réduction de la nicotine primé.
internationale. Le kit est actuellement en phase de préparation du marché, et nous sommes impatients de le présenter aux utilisateurs en temps voulu", a-t-il déclaré.*Red Dot Award : Marques et communication Design 2025À propos d'ELFBARELFBAR est un pionnier dans l'industrie
More news about: ELFBAR
Dec 08, 2025, 02:30 ET The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison
common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has grown into deeper layers of the bladder wall. These cancers, including subtypes T2, T3 and T4, are more likely to spread and are harder to treat.41 Globocan.
More news about: Photocure
Dec 08, 2025, 02:27 ET The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison
common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has grown into deeper layers of the bladder wall. These cancers, including subtypes T2, T3 and T4, are more likely to spread and are harder to treat.41 Globocan.
More news about: Photocure
Dec 08, 2025, 02:00 ET GOLD ROYALTY TO ACQUIRE PRODUCING PEDRA BRANCA GOLD AND COPPER ROYALTY
Mt at 1.68% copper and 0.47 g/t gold and indicated mineral resources of 12 Mt at 1.41% copper and 0.40 g/t gold, utilizing a cut-off based on an NSR value of $78.73/t. It also disclosed estimated proven mineral reserves at Pedra Branca of 1.3 Mt at 1.8% copper and 0.48 g/t gold and probable mineral reserves
More news about: Gold Royalty Corp.
Dec 08, 2025, 01:32 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Communications Anna ClarkT: +44.73.8.668.67.79 [email protected] Communications, Media RelationsLaurent SchotsT: +32.2.559.92.64
More news about: UCB
Dec 08, 2025, 01:28 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Communications Anna ClarkT: +44.73.8.668.67.79 [email protected] Communications, Media RelationsLaurent SchotsT: +32.2.559.92.64
More news about: UCB
Dec 08, 2025, 01:12 ET JETOUR T2 Served as Official Vehicle for G20 South Africa 2025
The JETOUR T2 launched in late October in Cape Town, South Africa. As a popular model in the JETOUR T-series, the T2 has achieved a cumulative global sales of 402,000 units within 26 months, ranking first in the "Light
More news about: Jetour